ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

174
Analysis
Health Care • South Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
Exchange Announcement • 17 Sep 2026 13:46

Material Business Matters Related to Investment Decisions

Exchange Announcement • 14 Sep 2026 13:54

Conclusion of Single Sales Contract or Supply Contract

Exchange Announcement • 10 Sep 2026 17:48

Organization of Investor Relations Event

Exchange Announcement • 10 Sep 2026 17:46

Material Business Matters Related to Investment Decisions(ë‡Œì „ì¦ ì‹ ì•½ 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 ìˆ˜ë ¹)

Exchange Announcement • 26 Aug 2026 17:03

Material Business Matters Related to Investment Decisions(License Agreement for Opakalim and Other Epilepsy Drug Candidates)

x